News and Information

DateTitle 
04/24/17Navidea/Macrophage Therapeutics selected for oral presentations and The Society of Nuclear medicine and Molecular Imaging (SNMMI) Annual Meeting in Denver.Printer Friendly Version
04/24/17Navidea selected by NIH/NIAMS to present Rheumatoid Arthritis program to investors at Bio International in San Diego June 19-22, 2017Printer Friendly Version
04/24/17Navidea/Macrophage Therapeutics Completes Sentinel Node Biopsy Evaluation in Prospective Study of Tc99m Tilmanocept in Cervical Cancer.Printer Friendly Version
04/24/17Navidea/Macrophage Therapeutics Completes Collaborative study of Tc99m Tilmanocept vs Filtered Sulfur Colloid Head-to-Head Study in Breast Cancer.Printer Friendly Version
04/24/17Navidea/Macrophage Therapeutics Receives Second Round NCI SBIR Awards for Kaposi's Sarcoma (KS) Imaging and Kaposi's Sarcoma Therapy.Printer Friendly Version
04/24/17Navidea/Macrophage Therapeutics Completes 18 Patient Rheumatoid Arthritis Diagnostic Imaging Review for Subcutaneous Tc99M-Tilmanocept Dose Escalation Study (NAV3-23).Printer Friendly Version
04/24/17Macrophage Therapeutics/Navidea Completes Three Therapeutic Animal Studies in NASH all with Positive Results.Printer Friendly Version
04/24/17Navidea/Macrophage Therapeutics and Kettering Medical Center (Dayton, OH) kick off intravenous Phase 1 dose escalation study in rheumatoid arthritis patients (NAV3-21) Printer Friendly Version
04/24/17Navidea/Macrophage Therapeutics and Massachusetts General Hospital publish results of Phase 1 Pilot Study of Tc99m-tilmanocpet imaging of HIV cardiovascular disease (Journal of Infectious Diseases). Printer Friendly Version
04/24/17Navidea/Macrophage Therapeutics WITH Massachusetts General Hospital complete Phase 1 Pilot Study in HIV Cardiovascular disease and Presentation of Results at Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, WA, February 13-16, 2017.Printer Friendly Version